Autism Science Foundation Weekly Science Report

Autism Science Foundation Weekly Science Report takes new autism papers one at a time and talks them through, stopping to explain terms, sample sizes and limits along the way. The subject range is wide. Across a handful of episodes it moves from the energy machinery inside cells to gene networks, birth timing, early intervention, age at diagnosis and mortality. Genetics draws real enthusiasm. In 'Genetic pathways leading to autism', the host describes an ASF-funded collaboration between researchers at UCLA and Stanford University. It looked at downstream genes shared by known genetic forms of autism and by idiopathic autism, and the host compares the process to falling dominoes. The host's point is practical: if separate genetic routes converge, one therapy might target the shared pathway. The epidemiology comes with caveats. A Finnish study of late preterm births shows neurodevelopmental disorders becoming less common as gestational age rises, and the host notes that those figures cover far more than autism. A CDC analysis traced death records for people who took part in earlier autism prevalence studies and compared them with people with intellectual disability or cerebral palsy. The host calls its figures a likely underestimate because of the participants' ages. Guest episodes change the shape of the show. Dr. Carissa Sorois of the University of Wisconsin discusses her review of mitochondrial dynamics in neurodevelopment, including why the brain is so hard to study directly and what post-mortem protein measurements can suggest. Dr. Giacomo Vivanti of the Drexel Autism Institute talks through a study of about 700 preschoolers who received different early intervention approaches, with spoken language as the outcome. The host points out how large that group is, since studies of this kind often follow far fewer children. Links to the guests' papers are promised in the podcast summary. Policy sits right beside the research. The host reports on the I-ACC, an independent committee formed to offer an alternative perspective to the federal IACC, and argues plainly that the idea linking vaccines to autism needs pushback. 'Can COVID cause autism?' acknowledges time spent countering misinformation about Tylenol and leucovorin after a September 22 press conference, then gets back to the studies: a California finding of no link between prenatal cannabis and autism, genetic factors tied to earlier diagnosis, and COVID as another illness associated with a higher probability of an autism diagnosis. Its closing includes everyday advice about vaccination, handwashing and keeping away from sick people. Alicia Halliday introduces herself on 'Rare Disease Week, the FDA, mortality in autism, trajectories and subcategories', which marks Rare Disease Week as a moment of growing awareness and asks about the renaming of antipsychotics as behavior-stabilizing medication. The delivery is conversational, with small asides such as calling cannabis one of the host's favorite topics, and suggestions for future episodes are invited by email.